Provided by Tiger Trade Technology Pte. Ltd.

Seres Therapeutics

8.60
-0.0500-0.58%
Volume:35.64K
Turnover:308.94K
Market Cap:77.80M
PE:14.42
High:8.97
Open:8.86
Low:8.48
Close:8.65
52wk High:29.98
52wk Low:6.53
Shares:9.05M
Float Shares:6.46M
Volume Ratio:1.30
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.5963
EPS(LYR):0.0175
ROE:15.95%
ROA:-40.12%
PB:1.78
PE(LYR):491.34

Loading ...

Seres Therapeutics (MCRB) Gets a Buy from Canaccord Genuity

TIPRANKS
·
Feb 13

Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash

Benzinga_recent_news
·
Feb 12

Seres Shares Down After Co Pauses Drug Development, Lays Off Workers

Dow Jones
·
Feb 12

BRIEF-Seres Provides Program And Corporate Updates And Prioritizes Emerging Programs In Inflammatory & Immune Diseases

Reuters
·
Feb 12

Seres Therapeutics Cuts Workforce by 30% and Shifts Focus to Early-Stage Programs

Reuters
·
Feb 12

Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

THOMSON REUTERS
·
Feb 12

Seres Therapeutics Inc: Company's Runway Extension Actions, Including Reducing Workforce by Approximately 30%

THOMSON REUTERS
·
Feb 12

Seres Therapeutics Inc: Expects to Extend Its Cash Runway Through Q3 of 2026

THOMSON REUTERS
·
Feb 12

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM

Reuters
·
Feb 12

Seres Therapeutics Reports SER-155 Reduces Bloodstream Infections in Stem Cell Transplant Patients

Reuters
·
Jan 06

Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy

GlobeNewswire
·
Jan 06

BUZZ-Seres Group's Hong Kong shares jump after joining stock connect program

Reuters
·
Dec 01, 2025

Seres Therapeutics Reports Positive Q3 2025 Results

TIPRANKS
·
Nov 06, 2025

Seres Therapeutics Q3 2025 Earnings Call Summary and Q&A Highlights: SER-155 Progress and Strategic Partnerships

Earnings Call
·
Nov 06, 2025

Seres (MCRB) Q3 2025 Earnings Call Transcript

Motley Fool Transcribing
·
Nov 06, 2025

Analysts’ Top Healthcare Picks: Seres Therapeutics (MCRB), Neurocrine (NBIX)

TIPRANKS
·
Nov 06, 2025

Seres Therapeutics Q3 net income $8.2 mln, reverses loss

Reuters
·
Nov 05, 2025

Seres Therapeutics Q3 EPS USD 0.94

Reuters
·
Nov 05, 2025

Seres Therapeutics Q3 EPS $0.94 Beats $0.67 Estimate, Sales $351.000K Miss $5.875M Estimate

Benzinga
·
Nov 05, 2025

Seres Therapeutics Inc: Expanding Understanding of Broader Ser-155 Therapeutic Opportunity, Expect Obtaining Initial Efficacy Results in Early 2026

THOMSON REUTERS
·
Nov 05, 2025